Bolivian call for tougher sanctions on counterfeit drugs

12 January 2010

Following the police seizure in Bolivia of some 40 tonnes of adulterated drugs between last December and January this year, there has been a call for more severe penalties on such activities for the authorities in the country.

It appears that the majority of counterfeits came from an importer company called ESKE SRL, which was selling drugs with expired use-by dates and, in others, it changed the expiration dates. Another company was producing high-consumption counterfeit medicines. It is reported that the head of the two companies will be prosecuted for crimes against public health that carries a penalty of up to seven years jail.

Bolivia's Minister of Health, Ramiro Tapia, reported that the government will start tracking counterfeit drugs, supported by students in biochemistry and policemen, and they will do so in all pharmacies around the country.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical